Premium
C‐type natriuretic peptide treatment and cardiovascular function in spontaneously hypertensive rats.
Author(s) -
Costa María Angeles,
Caniffi Carolina,
Cerniello Micaela,
Romero Mariana,
Sueiro Laura,
Radionovas Vanesa,
Arranz Cristina
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.708.4
Subject(s) - medicine , phenylephrine , cardiac function curve , ejection fraction , blood pressure , endocrinology , stroke volume , natriuretic peptide , ventricle , vasodilation , cardiac output , heart rate , aorta , nitric oxide synthase , cardiology , nitric oxide , heart failure
The aim was to evaluate the effects of C‐type natriuretic peptide (CNP) on systolic blood pressure (SBP), cardiac and vascular function, and nitric oxide synthase (NOS) activity on cardiac left ventricle (LV) and aorta artery (AA), in spontaneously hypertensive rats (SHR). Methods 12 weeks‐old male SHR were infused (14 days, osmotic pumps) with CNP (0,75 μg/hr.rat) or saline (S). SBP (mmHg) was recorded and echocardiography was performed. Animals were decapitated and NOS activity (pmol 14 C L‐citrulline/g.tissue. min) was measured in AA and LV. Vascular reactivity in AA was studied, evaluating maximal response to phenylephrine (Rmax) and concentration of acetylcholine (expressed as negative log molar) producing 50% of maximum relaxation (pEC50). Statistics: t‐test.S CNPSBP 175±3 159±5 * Heart rate (bpm) 435±10 434±15 End‐diastolic volume (ml) 0,16±0,02 0,23±0,03 * End‐systolic volume (ml) 0,05±0,02 0,07±0,03 Stroke volume (ml/min) 0,11±0,01 0,16±0,02 * Cardiac output (ml) 47,8±2,0 68,8±7,4 * Ejection fraction % 69±6 71±6 Fractional shortening % 34±5 35±4 NOS LV 255±5 371±8 * NOS AA 117±16 202±4 * Rmax 1,01±0,16 0,46±0.06 * pEC50 7,4±0,1 9,3±0.2 *Values are means ± SEM.* p<0.05 vs S; n=6 rats/group.Conclusion Chronic treatment with CNP decreased blood pressure, activating cardiovascular NOS, improving cardiac efficiency and vascular function, in this model of hypertension. Supported by: UBA‐Conicet.